Everyone knows that pathways and cost to FDA phase 3
But can I suggest looking at the tiny Market Cap of NYR versus the potential and $$ market this exposes them to
Personally I am not invested to prove points or argue about FDA - I am invested to opportunities - if this tracks well the MC wont stay here for long - no one blinks at companies with $100 million MC (that would be circa 8 bags from here)
Sure NYR may/probably will never not be a $billion Pharma with phase 3 trials (but that could happen) but definitely every chance a massive $billion Pharma comes along and funds products or buys out products
Market is about making money - and at this small cap end - by investing into undervalued companies with unrecognized potential
GLTAH
NYR Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)